Bone hydroxyapatite (HAp) (HAp)

Bone hydroxyapatite is the primary inorganic constituent of vertebrate bone and teeth, representing a complex, carbonated form of calcium phosphate [Ca10(PO4)6(OH)2] (StatPearls, 2023). It provides the essential mechanical strength and rigidity to the skeletal system while functioning as a dynamic reservoir for calcium and phosphate ions, crucial for systemic mineral homeostasis (NIH, 2023). This mineral matrix is not static but undergoes continuous remodeling through the balanced actions of osteoblasts and osteoclasts (PubMed, 2022). In a therapeutic context, hydroxyapatite serves as a specific docking site for bone-seeking agents, most notably bisphosphonates, which bind to the mineral surface with high affinity via their phosphonate groups (Nancollas et al., 2006). This interaction allows for the targeted delivery of drugs to sites of active bone remodeling, making it central to the treatment of metabolic bone diseases such as osteoporosis and Paget's disease (StatPearls, 2023). Furthermore, its high affinity for certain isotopes, such as Radium-223, is exploited in nuclear medicine for both the imaging and treatment of bone metastases (Parker et al., 2013).

Other names

Carbonated hydroxyapatiteCarbonated apatiteBone mineralBio-apatiteHydroxylapatiteCalcium hydroxyapatite

Drugs such as bisphosphonates and certain radiopharmaceuticals target bone hydroxyapatite through high-affinity coordination bonds with calcium ions in the mineral lattice (Nancollas et al., 2006). This binding facilitates the localization of these agents to the bone surface, particularly at sites of active remodeling. Once bound, bisphosphonates are internalized by osteoclasts during bone resorption, where they subsequently inhibit intracellular enzymes like farnesyl pyrophosphate synthase, leading to reduced bone loss (StatPearls, 2023).